Pharmacist Insights: Baloxavir Marboxil (Xofluza)


The FDA initially approved baloxavir marboxil in October 2018 for the treatment of acute, uncomplicated influenza.

In 2019, the FDA approved single-dose baloxavir marboxil (Xofluza, Genentech) for use in patients who are at a high risk of developing influenza-related complications.

The FDA initially approved baloxavir marboxil in October 2018 for the treatment of acute, uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. The approval marked the first new antiviral flu treatment with a novel mechanism of action backed by the agency in nearly 20 years.

Baloxavir marboxil was the first antiviral medication approved specifically for this use. Baloxavir marboxil has a novel mechanism of action that inhibits polymerase acidic endonuclease, which is an enzyme essential for viral replication.

Individuals with chronic conditions or those aged 65 years and older are typically at a higher risk of developing flu complications, which can range from sinus or ear infections to more serious events, such as pneumonia.

The supplemental New Drug Application approval was based on results from the phase 3 CAPSTONE-2 study, which included individuals aged 12 years and older who were at high risk of complications from the flu. The study compared a single dose of 40 mg or 80 mg of baloxavir marboxil with oseltamivir (75 mg twice daily for 5 days), versus placebo.

According to the data, baloxavir marboxil significantly reduced time to improvement of flu symptoms compared with placebo in those at high risk of complications (median time 73 hours versus 102 hours; p<0.001). Additionally, similar efficacy results were observed between baloxavir marboxil and oseltamivir in relation to duration of symptoms (median time 73 hours versus 81 hours).

For those with type B virus, the median time to improvement of flu symptoms was shorter in the baloxavir marboxil compared with the placebo group (75 hours versus 101 hours, respectively).

Overall, adverse events reported in the study included diarrhea, bronchitis, nausea, sinusitis, and headache. Baloxavir marboxil was generally well tolerated, with no new safety signals identified.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.